Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: SG who wrote (172)	11/1/1997 7:49:00 AM
From: Haolin Ni	Read Replies (1) \| Respond to of 645

Pls read all my posts. This company is not good one for you looking for a kill. You may be killed by it. Now there are so many cheap stocks available and stick to AVIR is definitely not good choice. The FDA approval is about two years away. You could certainly buy it under $20 even under $15 if you set a order good untill cancelled. You must know flu vaccine could not have a earning explosion but any good tech company could. Therefore, you should looking for a kill from the tech company instead of a biotech company. Even within the biotech company, a lot of the biotech stocks are better than AVIR, a single products company known have limited earning in the future even if it could be approval by FDA. Good luck!

To: SG who wrote (172)	11/1/1997 11:11:00 AM
From: Vector1	Read Replies (3) \| Respond to of 645

Ta all, I don't post very much on this thread but for those who have an interest in the stock the following are the events that will drive the stock over the next 12 months. Haolin please to do not post back to me I will not respond. COMING EVENTS: (1) Initiation of Phase I/II trial with EBV vaccine on track for 4Q:97; (2) Phase III study of CAIV in the elderly fully enrolled, data expected in 1998; (3) completion of enrollment in large field study of CAIV in healthy adults now through 1Q:98; (4) conducting Phase II trial of bovine parainfluenza type 3 vaccine 3Q:97 through 1Q:98; (5) corporate partnership for CAIV; (6) PLA filing for CAIV vaccine expected in mid-1998; and (7) filing of an IND for a recombinant CMV vaccine planned for mid-1998[BRS1]. V1